1 **Recreational and occupational physical activity and risk of adverse events** in truncating MYBPC3 founder variant carriers 2 3 Fahima Hassanzada, MD^{a,b,*}, Mark Jansen, MD, PhD^{a,b,c,*}, Freyja H.M.van Lint, MD^{a,b,d,e*}, 4 Laurens P. Bosman, MD, PhD^{b,c}, Amand F. Schmidt, PhD^{b,c,f}, Dennis Dooijes, PhD^{a,b}, Danny 5 van de Sande, MD, PhD^c, Bristi Miah, MSc^a, Saskia N. van der Crabben, MD, PhD^{b,e}, Arthur 6 A.M. Wilde, MD, PhD^{b,i}, Ronald H. Lekanne Deprez, MD, PhD^{b,e}, Rudolf A. de Boer, MD, 7 8 PhD^{b,k,l}, Imke Christiaans, MD, PhD^m, Jan D.H. Jongbloed, PhD^m, Harald T. Jorstad, MD, PhD^j, Folkert W. Asselbergs, MD, PhD^{b,i,n}, J. Peter van Tintelen, MD, PhD^{a,b,e}, Annette F. 9 Baas, MD, PhD^{a,b}, Anneline S.J.M. te Riele, MD, PhD^{b,c} 10 11 * These authors contributed equally 12 13 **Affiliations:** 14 ^a Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the 15 Netherlands. 16 ^b 'Member of the European Reference Network for rare, low prevalence and complex diseases of the heart: ERN GUARD-Heart' (ERN GUARDHEART; http://guardheart.ern-net.eu). 17 18 ^c Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, 19 the Netherlands. 20 ^d Department of Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. 21 ^e Department of Human Genetics, Amsterdam University Medical Center, University of 22 Amsterdam, the Netherlands. 23 ^f Netherlands Heart Institute, Utrecht, the Netherlands. 24 ^g Institute of Cardiovascular Science, Faculty of Population Health Sciences, University 25 College London, London, UK. 26 ^h Department of Cardiology, University Medical Center Groningen, University of Groningen, 27 Groningen, the Netherlands. 28 ⁱ Department of Cardiology, University Medical Centre Amsterdam, University of 29 Amsterdam, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences, Heart Failure 30 and Arrhythmias, University Medical Centre Amsterdam, Amsterdam, the Netherlands. 31 ^j Department of Cardiology, Heart Center, Amsterdam UMC, University of Amsterdam, 32 Amsterdam Movement Sciences, Amsterdam Cardiovascular Sciences, Amsterdam, The

33 Notified high print reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ¹ ^k University Medical Center Groningen, University of Groningen, Department of Cardiology,
- 2 Groningen, the Netherlands.
- ³ ¹ Department of Cardiology, Thorax Center, Erasmus University Medical Center, Erasmus
- 4 University Rotterdam, Rotterdam, the Netherlands.
- ⁵ ^m Department of Genetics, University Medical Centre Groningen, University of Groningen,
- 6 Groningen, the Netherlands.
- ⁷ ⁿ Health Data Research UK and Institute of Health Informatics, University College London,
- 8 London, United Kingdom.
- 9
- 10 Short title: Exercise in *MYBPC3* founder variants carriers
- 11
- 12 Address for correspondence:
- 13 Fahima Hassanzada
- 14 Department of Genetics, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX
- 15 Utrecht, the Netherlands
- 16 Telephone number: +31-650124657
- 17 E-mail: f.hassanzada-4@umcutrecht.nl
- 18
- 19 Total word count: 5568
- 20

1 Abstract

2	Background: MYBPC3 founder variants cause hypertrophic cardiomyopathy (HCM) leading
3	to heart failure (HF) and malignant ventricular arrhythmias (MVA). Exercise is typically
4	regarded a risk factor for disease expression, although evidence is conflicting. Stratifying by
5	type of exercise may discriminate low- from high-risk activities in these patients.
6	Objective(s): Evaluate effects of exercise, stratified by high-static and high-dynamic
7	component, on risk of major cardiomyopathy-related events (MCE) and cardiomyopathy
8	penetrance among MYBPC3 founder variant carriers.
9	Methods: We interviewed 188 carriers (57% male, 43.4±14.8 years) on exercise participation
10	since age ten. Exercise was quantified as metabolic equivalent task (MET)-hours/week before
11	presentation. MCE was defined as a composite of MVA (sustained ventricular
12	tachycardia/fibrillation), HF (HF hospitalizations or transplantation), and septal reduction
13	therapy. Static and dynamic exercise were defined per Bethesda classification. Associations of
14	exercise with MCE and cardiomyopathy penetrance were adjusted for sex and assessed using
15	Cox regression.
16	Results: Overall, 40 (21%) subjects experienced MCE and 139 (74%) were diagnosed with
17	cardiomyopathy. No association was found for overall physical activity and high-static
18	activity with MCE (p=0.900 overall; p=0.274 high-static) or cardiomyopathy penetrance
19	(p=0.787 overall; p=0.774 high-static). In contrast, high-dynamic activity was associated with
20	MVA (dichotomized at 75 th percentile: adjusted hazard ratio 2.70, 95% confidence interval
21	1.01-7.24, p=0.049).
22	Conclusions: Overall exercise participation does not generally increase the risk of adverse
23	events among MYBPC3 founder variant carriers. Nonetheless, an increased risk of MVA was
24	observed among those engaged in the highest quartile of high-dynamic-sports, suggesting that
25	high-level high-intensity exercise activities should be entertained with caution.

1 Keywords: HCM, high dynamic exercise, adverse events, ventricular arrhythmia, MYBPC3

1 Abbreviations and Acronyms

- 2 aHR = adjusted hazard ratio
- 3 HCM = hypertrophic cardiomyopathy
- 4 HF = heart failure
- 5 ICD = implantable cardioverter-defibrillator
- $6 \quad LV = left ventricular$
- 7 MCE = major cardiomyopathy-related events
- 8 MET = metabolic equivalent of task
- 9 MVA = malignant ventricular arrhythmia
- 10 SRT = septal reduction therapy
- 11 *MYBPC3* = myosin binding protein C3 gene

1 Introduction

Hypertrophic cardiomyopathy (HCM) is a relatively common inherited heart disease with an estimated prevalence of 1:500.¹ It is characterized by left ventricular hypertrophy which is not explained by abnormal loading conditions.² Clinical presentation is heterogeneous with many patients remaining mildly symptomatic or asymptomatic, while others present with left ventricular (LV) outflow tract obstruction requiring septal reduction therapy (SRT), malignant ventricular arrhythmias (MVA) or debilitating heart failure (HF). This heterogeneity suggests an influential role of environmental factors.³

9 HCM is predominantly caused by variants in genes encoding sarcomeric proteins. In approximately 50% of patients, a likely pathogenic or pathogenic variant is found.^{4,5} Variants 10 11 are most frequently found in the MYBPC3 gene, encoding cardiac myosin-binding protein C, an important regulator of cardiac contractility.⁶ In the Netherlands, approximately 20% of 12 13 HCM patients carry a truncating *MYBPC3* founder variant.⁷ These variants lead to truncation 14 of MYBPC3 mRNA and subsequent haploinsufficiency of cardiac myosin-binding protein C, which has been shown to impact prognosis similar to other truncating MYBPC3 variants.^{8,9} 15 16 As HCM has frequently been reported in young athletes suffering sudden cardiac death, guidelines have traditionally discouraged competitive exercise in HCM patients.¹⁰⁻¹² 17 18 Exercise is hypothesized to contribute to sudden cardiac death in HCM by several 19 mechanisms, including increasing LV wall thickness and outflow tract obstruction, inducing 20 metabolic disturbances or ischemia, as well as pro-arrhythmic effects by adrenergic stimulation and/or fibrosis formation.^{12,13} However, several studies investigating effects of 21 22 exercise in HCM have not reported negative effects, with a single study even showing a protective effect on all-cause and cardiovascular mortality.¹⁴⁻¹⁶ Of note, none of these studies 23 24 assessed specific types of exercise, such as a distinction between static and dynamic

properties.¹⁵ High-static exercise, for example, may theoretically be more likely to contribute
 to hypertrophic remodeling, compared with high-dynamic exercise.^{17,18}

Therefore, we evaluated the effect of recreational and occupational physical activity on risk of major cardiomyopathy-related events (MCE) and cardiomyopathy penetrance in carriers of truncating *MYBPC3* founder variants, stratified by high-static and high-dynamic properties.

7

8 Methods

9 Patient population

10 This study is embedded in the BIO For CARe (Identification of BIOmarkers of HCM

11 development and progression in Dutch *MYBPC3* Founder variant CARriers) and UNRAVEL

12 (<u>www.unravelrdp.nl</u>) registries.^{19,20} Carriers of the c.2373dupG, c.2827C>T,

13 c.2864_2865delCT and c.3776delA MYBPC3 founder variants were recruited from three

14 Dutch university medical centers (Utrecht, Groningen and Amsterdam). The Institutional

15 Review Board, Medical Ethics Committee of UMC Utrecht gave ethical approval for this

16 work, with local approval at the Amsterdam UMC and UMC Groningen. All individuals

17 provided written informed consent.

18

19 Clinical data and outcomes

20 Clinical data were obtained from electronic health records and collected using pre-specified

21 electronic case report forms, as previously described.¹⁹ Collected data included sex, date

of birth, date and type of clinical presentation, hospitalization records, and results of (non-)

23 invasive studies (12-lead electrocardiogram [ECG], 2-dimensional transthoracic

24 echocardiography, and cardiac magnetic resonance imaging). Clinical presentation was

defined as the first medical visit for cardiac screening and/or symptoms related to *MYBPC3* in
 one of the enrolling centers.

The primary outcome was a composite of MCE, constituting of MVA (defined as sustained ventricular tachycardia, defined as ≥30 seconds at ≥100 beats per minute and resulting in hemodynamic instability or requiring termination, aborted cardiac arrest or sudden cardiac death), HF events (defined as HF hospitalization, ventricular assist device implantation, heart transplantation or HF-related mortality), and SRT (defined as septal myectomy or alcohol septal ablation).

9 Secondary outcomes were MVA, HF events, and SRT, analyzed as separate outcomes. 10 In addition, we evaluated the development of an overt cardiomyopathy diagnosis as secondary 11 outcome measure. For the latter, HCM was defined as a maximum left ventricular wall thickness of ≥ 13 mm not explained by abnormal loading conditions;¹¹ dilated cardiomyopathy 12 (DCM) as dilation of left ventricle with a left ventricular ejection fraction (LVEF) <45%;²¹ 13 14 Non-compaction cardiomyopathy (NCCM) as left ventricular non-compaction fulfilling the Jenni or Petersen criteria and a LVEF <50%,^{22,23} all not explained by abnormal loading 15 16 conditions or coronary artery disease. Individuals with LVEF <50% but without other criteria 17 for a specific cardiomyopathy diagnosis were classified as cardiomyopathy not otherwise 18 specified (CMP-NOS).

19

20 **Physical activity interviews**

Structured telephone interviews were conducted by three research assistants and one physician. Details of the exercise interview have been described previously.^{24,25} In short, physical activity was documented since age 10 years onwards using a pre-defined data collection sheet for all recreational and occupational physical activity. For each entry, the intensity (light, moderate or vigorous) and duration of physical activity were registered.

Subsequently, the corresponding metabolic equivalents (METs) were assigned using the
 Ainsworth et al. compendium of physical activities.²⁶

3 We assessed the impact of physical activity from age 10 years until presentation by 4 stratifying in: (i) overall physical activity; and (ii) physical activity during high-static and 5 high-dynamic sports. Overall physical activity was quantified as the average MET-6 hours/week spent on any physical activity and analyzed both in quartiles (based on the data) 7 and based on increments of 7.5 MET-hours/week (which is the American Heart Association's 8 recommended minimum physical activity) to compare physical activity to standardized 9 recommendations. High-static and high-dynamic sports were classified according to the 36th 10 Bethesda Conference Classification of Sports (Supplemental Figure 1) and quantified as MET-hours/week spent on this specific activity.^{17,27} In this study, sport activities in categories 11 12 IIIA, IIIB and IIIC were classified as high-static; and sport activities in categories IC, IIC and 13 IIIC as high-dynamic. Of note, class IIIC overlaps in both high-static and high-dynamic 14 categories. As high-static and high-dynamic activity categories were analyzed separately, the 15 use of class IIIC in both categories was statistically permitted.

16

17 Statistical analysis

18 Analyses were performed in R software (version 4.2.2). Continuous variables were expressed

19 as mean \pm standard deviation or median [interquartile ranges (IQR)] as appropriate and

20 compared using independent samples t-tests or Mann-Whitney U tests, respectively.

21 Categorical variables were presented as frequencies (percentage) and compared using the chi-

22 square or Fisher's exact test. Physical activity before and after presentation were compared

23 using the Wilcoxon signed rank test.

Cumulative freedom from the composite outcome was determined by the KaplanMeier method and Cox-proportional hazard model. Follow-up was considered to start at first

1 clinical presentation and end at the date of reaching the endpoint or censoring (i.e. death from 2 any other cause or most recent follow-up at which the endpoint could be ascertained). 3 Schoenfeld residuals test was used to check the proportional hazard assumption. The linearity 4 assumption in the Cox model was assessed using Martingale residuals. In the absence of 5 established cut-off points for sport class-specific activities, medians and 75th percentile were used to dichotomize activities in case of significant non-linearity.²⁸ Multivariable Cox 6 7 regression was performed to correct for potential confounding from sex. Sensitivity analyses 8 were performed by restricting the analyses to patients diagnosed with a cardiomyopathy 9 diagnosis at first presentation. P-values <0.05 were considered statistically significant 10 throughout. 11 12 Results **Study population** 13 14 We included 188 carriers of truncating MYBPC3 founder variants. Their clinical 15 characteristics are provided in Table 1. Overall, 108 (57%) were male, with a mean age 16 43.4 ± 14.8 years at first presentation. Almost half (n=80, 43%) of study subjects were 17 probands. Maximum wall thickness was 16±6 mm with a mean LV ejection fraction of 59% 18 ± 10 and a LV end-diastolic diameter of 46 ± 6 mm. At first clinical evaluation, 104 (55%) had 19 a diagnosis of cardiomyopathy, most commonly HCM (n=98, 52% of overall population) 20 (Supplemental Table 1). 21 22 **Physical activity history** 23 Before first medical contact, study participants were physically active for a median of 56 [26-24 111] MET-hours/week, of which 15 [6-29] MET-hours were spent on recreational activity,

and 34 [4-84] MET-hours on occupational activity. High-dynamic activity was more

frequently entertained (10 [3-23] MET-hours/week) than high-static activity (0.1 [0-2] MET hours/week).

3	After presentation, median activity decreased to 38 [14-106] MET-hours/week
4	(p=0.021 compared to presentation). This was driven by a drastic decrease in occupational
5	activities to 11 [0-73] MET-hours/week (p=0.022 compared to presentation), whereas
6	recreational activities remained unchanged 14 [5-31] MET-hours/week (p=0.435 compared to
7	presentation). While there was no significant change observed in high-static activities
8	between presentation and follow-up (p=0.324), a reduction was noted in high-dynamic
9	activities, p<0.001 compared to presentation. Boxplots of physical activity before and after
10	presentation are provided in Supplemental Figure 2.
11	
12	Major Cardiomyopathy-related Events
13	In total, the primary endpoint (i.e. MCE) occurred in 40 (21%) individuals. This included 20
14	(11%) MVA events, 13 (7%) HF events, and 15 (8%) SRT events. Combinations of events
15	occurred in eight (4%) individuals (three subjects with both MVA and HF, two subjects with
16	both HF and SRT, and three subjects with MVA and SRT). None of the study subjects
17	presented with MCE and median time to first MCE was 6.6 [2.2-11.9] years after
18	presentation. There were no statistically significant differences in age (p=0.816) and sex
19	(p=0.351) between those with and without MCE. In contrast, LV hypertrophy (21 vs. 14 mm,
20	p<0.001) and LV ejection fraction (55 vs. 60%, p=0.011) were significantly different in those
21	with vs. without MCE, respectively.
22	Figure 1A shows the effect of overall physical activity on the primary endpoint. As
23	can be appreciated, no difference was observed for MCE occurrence between quartiles of

24 overall physical activity measured in MET-hours/week (p=0.374).

1	Figure 1B and C show the effect of high-dynamic activity and high-static activity on
2	MCE occurrence, respectively. As shown, there were no significant differences between
3	quartiles of either activity category for MCE (p=0.879 for high-dynamic activity; and p=0.125
4	for high-static activity).
5	
6	Secondary Endpoints
7	Malignant ventricular arrhythmias:
8	None of the individuals had experienced MVA at presentation. A total of 20 (11%) subjects
9	experienced MVA by last follow-up, on average 6.8 [3.3-12.6] years after presentation. No
10	differences were observed in age ($p=0.998$) or sex ($p=0.063$) between those with and without
11	MVA.
12	Supplemental Figure 3A show the effect of overall physical activity and 3C the effect
13	of high-static activity on MVA occurrence, respectively. As shown, there were no significant
14	differences between quartiles of either activity category for MVA (p=0.130 for overall
15	physical activity; and p=0.325 for high-static activity). As can be appreciated in Supplemental
16	Figure 3B, an increased risk of MVA was observed among those engaged in the highest
17	quartile of high-dynamic activities (p=0.041 compared to the lowest quartile of high-dynamic
18	activities).

Assessing the impact of high-dynamic activity on the risk of MVA, a violation of
linearity assumption of Cox proportional hazard was observed hence values of high-dynamic
activity for this endpoint were dichotomized by its 75th percentile. As shown in Figure 2,
high-dynamic exercise was associated with MVA when dichotomized by its 75th percentile
(23 MET-hours/week, aHR 2.70, 95% CI 1.01-7.24, p=0.049).

24 <u>Heart failure events:</u>

1	None of the individuals had experienced HF events at presentation. A total of 13 (7%)
2	subjects experienced HF events by last follow-up, on average 7.1 (3.2-13.9) years after
3	presentation. No differences were observed in age (p=0.618) or sex (p=0.581) among those
4	with and without HF events.
5	Supplemental Figure 4A shows the effect of overall physical activity on HF events. As
6	can be appreciated, no difference was observed for HF occurrence between quartiles of
7	overall physical activity measured in MET-hours/week (p=0.954).
8	Supplemental Figure 4B and C show the effect of high-dynamic activity and high-
9	static activity on HF occurrence, respectively. There were no significant differences between
10	quartiles of either activity category for HF events (p=0.490 for high-dynamic activity; and
11	p=0.834 for high-static activity).
12	
13	Septal reduction therapy
14	None of the individuals had experienced SRT at presentation. A total of 15 (8%) subjects
15	experienced SRT by last follow-up, with a median 7.1 [3.3-13.9] years after presentation. No
16	differences were observed in age (p=0.525) or sex (p=0.964) among those with and without
17	SRT.
18	Supplemental Figure 5A shows the effect of overall physical activity on SRT. No
19	difference was observed for SRT between quartiles of overall physical activity measured in
20	MET-hours/week (p=0.539).
21	As shown in Supplemental Figure 5B (high-dynamic activity) and C (high-static
22	activity), there were no significant differences between quartiles of either activity category for
23	SRT (p=0.473 for high-dynamic activity; and p=0.072 for high-static activity).
24	
25	Cardiomyopathy penetrance

1	A total of 104 (55%) subjects were diagnosed with cardiomyopathy (98 HCM, 3 DCM
2	[possibly HCM in the "burned-out phase"], 2 CMP-NOS and 1 NCCM) at first clinical
3	evaluation. During a median 7.4 [3.9-14.6] years of follow-up, 35 (19%) additional subjects
4	developed cardiomyopathy, all of whom with an HCM diagnosis. This culminated to a total of
5	139 (74%) patients with cardiomyopathy by last follow-up.
6	Figure 3A shows the effect of overall physical activity on cardiomyopathy penetrance.
7	As can be appreciated, no difference was observed in cardiomyopathy penetrance between
8	quartiles of overall physical activity measured in MET-hours/week (p=0.208).
9	Figure 3B and C show the effect of high-dynamic activity and high-static activity on
10	cardiomyopathy penetrance, respectively. No significant differences between quartiles of
11	either activity category for cardiomyopathy penetrance were identified (p=0.701 for high-
12	dynamic activity; and p=0.718 for high-static activity).
13	
14	Sensitivity analysis
15	Our study population included a sizable number of subjects without phenotypic expression,
16	which may influence our ability to pick up significant differences among groups. We

17 therefore repeated the analyses solely in individuals with a cardiomyopathy diagnosis as

18 sensitivity analysis. Clinical characteristics of subjects with a cardiomyopathy diagnosis are

19 provided in Supplemental Table 2. In Supplemental Tables 3 and 4, it is shown that results

20 were identical to the main results.

21

22 **Discussion**

23 In this study, we evaluated the effects of physical activity stratified by type of activity on

24 clinical outcomes and cardiomyopathy penetrance in 188 carriers of truncating MYBPC3

25 founder variants. We assessed overall physical activity both in quartiles based on our data,

and based on the American Heart Association's recommended minimum for healthy adults
 (7.5 MET-hours/week). High-dynamic and high-static activities were classified as per
 Bethesda classification and evaluated in quartiles since there is no recommended cutoff for
 these types of activity.

5 Our findings revealed that neither overall physical activity nor high-static exercise 6 increased the risk of MCE and cardiomyopathy penetrance. In contrast, when analyzing the 7 combined endpoint by its separate components, we observed that high-dynamic exercise 8 increased the risk of MVA when dichotomized by its 75th percentile, which was equivalent to 9 more than 23 MET-hours/week. For example, this is reached when an individual spends 50 10 minutes on vigorous swimming (9.8 METs/hour) for 3 days per week, or participates in 50 11 minutes of vigorous running (10 METs/hour) 3 days per week, or in 1.5 hours of vigorous 12 soccer (10 METs/hour) 2 days per week.

13

14 **Physical activity and risk of MCE and cardiomyopathy penetrance**

Physical activity has been traditionally considered as a risk factor for patients with HCM. 15 which has resulted in conservative exercise recommendations. However, several recent 16 17 studies have shown neutral or even beneficial effects of exercise in HCM. Saberi et al. 18 assessed the impact of moderate-intensity exercise compared to usual activity in a preliminary 19 randomized controlled trial including 136 patients with HCM. Not only did they not observe 20 any MVA in either group, but they additionally observed a small but statistically significant increase in peak oxygen consumption in the moderate-intensity exercise group.²⁹ 21 22 Consistently, Klempfner et al. did not observe adverse events and showed increased 23 functional capacity in a single-arm trial including 20 patients with symptomatic HCM who underwent a cardiac rehabilitation exercise program.³⁰ Leveraging a nationwide population-24 based cohort, Kwon et al. observed decreases in all-cause and cardiovascular mortality for 25

1 increasing tertiles of physical activity among 7666 patients with HCM during more than 5 years of follow-up.¹⁶ Likewise, in a retrospective, cross-sectional study, Andreassen et al. 2 3 observed a positive association between exercise training during childhood and LV diastolic 4 function in 121 patients with HCM and 66 carriers of HCM-associated genetic variants.³¹ 5 Some authors have suggested that exercise restrictions have negative psychological effects in 6 athletic patients with HCM, and may result in increased risks of cardiovascular disease resulting from a sedentary lifestyle.^{32,33} In sharp contrast to the abovementioned reassuring 7 8 findings, however, in a small series Aengevaeren et al. found that HCM patients with 9 increasing tertiles of physical activity were younger at the time of diagnosis and more frequently had a history of non-sustained ventricular tachycardia.¹⁵ 10 11 A recent large prospective study shed light on this matter. In this study, Lampert et al. 12 did not observe a higher rate of death or life-threatening arrhythmias among 1660 individuals 13 with HCM exercising vigorously than those participating in moderate exercise.³⁴ Of note, the 14 authors used a cut-off of 360 MET-hours/year to define vigorous exercise, which is equivalent 15 to approximately 7 MET-hours/week. This aligns closely with the AHA's minimum 16 recommended exercise level of 7.5 MET-hours/week for healthy adults. For example, this is 17 reached when an individual spends one hour on vigorous bicycling (7.8 METs/hour) 1 day per week. This is a much lower cut-off than the 23 MET-hours/week that we used for the 75th 18 19 percentile of high-dynamic exercise, possibly explaining the observed difference between our studies. In line with the results of Lampert et al.,³⁴ we found that overall physical activity and 20 high-static exercise did not significantly increase the risk for any of our outcomes in carriers 21 22 of truncating MYBPC3 variants. Our study thus confirms and extends prior research, since our 23 detailed data collection also allowed for sub-analyses stratified by specific types of exercise 24 (i.e. by dynamic or static component), which may be more suitable to uncover possibly detrimental effects on clinical course in this patient population. Regardless of the available 25

evidence, future prospective studies will be pivotal to better understand the interaction
 between exercise, HCM-related outcomes and general health benefits, in order to improve
 exercise recommendations for this generally young patient population.

4

5 High-dynamic exercise and MVA

6 To the best of our knowledge, our study was the first to specifically assess high-dynamic and 7 high-static exercise as potential predictors of cardiomyopathy-related outcomes. While we did 8 not find an association between high-static exercise with any of our study outcomes, our data 9 shows that those who participated in the highest quartile of high-dynamic exercise had 10 increased risk of MVA suggesting that these activities should be entertained with caution. The 11 exact mechanism underlying the association of high-dynamic exercise and MVA in these 12 patients is not fully understood. Previous studies have proposed several factors such as 13 heterogenous myocardial blood flow, myocardial disarray, associated abnormalities of the 14 vascular response to exercise, electrolyte and sympathetic-vagal imbalance, and exerciseinduced metabolic acidosis.^{13,35-38} More research in (pre-)clinical disease models may shed 15 further light on this issue. 16

17

18 High-static exercise and disease course

Our results showed that high-static exercise did not increase the risk of MCE and cardiomyopathy penetrance among *MYBPC3*-founder variant carriers. Whether high-static exercise can be considered safe, or whether there could be an effect of more intensive highstatic exercise on disease course, cannot be determined from our data. Furthermore, caution is needed in those patients with LV outflow tract obstruction at rest or during exercise.³⁹⁻⁴¹ Of note, out of 26 individuals with LV outflow tract obstruction in our study, one was engaged in frequent high-static exercise (>2 MET-hours/week), who experienced MCE. Therefore, we

emphasize the importance of shared decision making for participation in more intensive static
and also dynamic exercise. Future prospective studies are required to personalize exercise
recommendations and to determine the optimal exercise threshold that is safe in this patient
population.

5

6 Limitations and Clinical Implications

To our knowledge, this is the first and largest interview-based exercise study in a genetically homogenous HCM population. Genotype-driven inclusion allowed us to assess cardiomyopathy penetrance as an outcome. Additionally, the design of the interview allowed us to assess specific categories of physical activity. This provides a foundation for future prospective studies to evaluate the effect of specific types of exercise on the disease course of patients with HCM and may contribute to finetuning exercise recommendations for these patients, balancing potential benefits of exercise with exercise-related risks.

14 Some limitations warrant consideration. The retrospective nature of this study results 15 in ascertainment bias and missing data. Recall bias and social desirability bias may have 16 resulted in over- or underreporting of physical activities. As carriers were required to be alive 17 for the exercise interview, severely affected carriers that passed away before initiation of this 18 study could not be included. Restricting inclusion to truncating MYBPC3 variants may limit 19 generalizability to the wider HCM population. Furthermore, the intensity of physical activity 20 was only taken into account in the calculation of the number of MET-hours/week. However, 21 different intensities of exercise could contribute to hypertrophic remodeling to differing degrees, e.g. vigorous exercise may be more detrimental than mild to moderate intensity 22 23 exercise. Despite being the largest interview-based study in a genetically homogenous HCM 24 population, sample size was still not sufficient to control for additional potential cofounding 25 variables such as hypertension and body mass index. Additionally, we did not inquire about

the use of anabolic steroids or other exercise-enhancing drugs and supplements, which could modify or confound the apparent effects of exercise in some carriers. Finally, in the absence of established cut-off values for high-static and high-dynamic exercise, we used data-driven cut-off values, which limit direct interpretation and may result in overfitting. Taken together, these limitations emphasize the importance of prospective validation of our results.

6

7 Conclusions

8 In truncating *MYBPC3* founder variant carriers, overall physical activity and high-static 9 exercise are not associated with an increased risk of MCE and cardiomyopathy penetrance. 10 However, those who participated in the highest quartile of high-dynamic exercise had 11 increased risk of MVA, suggesting that these activities should be entertained with caution. 12 Taken together, these findings may contribute to improving exercise recommendations in 13 HCM patients. We envision a more individualized approach and support the restrictions of 14 very frequent high-intensity exercise in HCM patients. Future studies are needed to 15 prospectively validate these findings.

1 Clinical perspectives

Competency in medical knowledge: The impact of different types of exercise on the risk of 2 3 major cardiomyopathy-related events and cardiomyopathy penetrance in truncating MYBPC3 4 founder variant carriers is unknown. We found that only those who participated in the highest 5 quartile of high-dynamic exercise had increased risk of malignant ventricular arrhythmias; all 6 other types of exercise did not result in increased risk of major cardiomyopathy-related events 7 or cardiomyopathy penetrance. This suggests that while most exercise may be considered 8 safe, very frequent high-dynamic exercise should be entertained with caution. 9 Translational outlook: Further prospective research is necessary to validate these findings and 10 determine safe thresholds and/or intensities of high-dynamic and high-static exercise for

11 patients with cardiomyopathy, specifically HCM and carriers of pathogenic genetic variants.

1 Acknowledgements

- 2 We thank all study participants who made this study possible.
- 3

4 Sources of funding

- 5 This work was supported by the Netherlands Cardiovascular Research Initiative with the
- 6 support of the Dutch Heart Foundation (CVON2014-40 DOSIS, Dutch Cardiovascular
- 7 Alliance 2020B005 DoubleDose to A.F.B, F.W.A., J.P.v.T., M.M. and R.A.d.B.; CVON2015-
- 8 12 e-Detect to F.W.A, J.P.v.T. A.S.J.M.t.R. and I.C.), the Dutch Heart Foundation (Dekker
- 9 2015T041 to A.F.B. and M.J), ZONMw Off Road 2021 to ASJMtR, European Research
- 10 Counsil HORIZON IMPACT (grant no. #101115536 to A.S.J.M.t.R.), University College
- 11 London Hospitals National Institute for Health and Care Research Biomedical Research
- 12 Centre (to F.W.A.), and British Heart Foundation (PG/18/5033837, PG/22/10989 and
- 13 University College London/British Heart Foundation Research Accelerator AA/18/6/34223 to
- 14 A.F.S.). Dr. de Boer is supported by the Netherlands Heart Foundation (grants 2017-21; 2017-
- 15 11; 2018-30;), by the leDucq Foundation (Cure-PLaN), and by the European Research
- 16 Council (ERC CoG 818715).

17

18 Disclosures

19 Dr. De Boer received research grants and/or fees from AstraZeneca, Abbott, Boehringer

20 Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and

- 21 Roche; and has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers
- 22 Squibb, Novartis, and Roche.

1 References

2	1.	Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of
3		hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249-1254. doi:
4		10.1016/j.jacc.2015.01.019
5	2.	Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C,
6		Bezzina CR, Biagini E, Blom NA, de Boer RA, et al. 2023 ESC Guidelines for the
7		management of cardiomyopathies. Eur Heart J. 2023;44:3503-3626. doi:
8		10.1093/eurheartj/ehad194
9	3.	Repetti GG, Kim Y, Pereira AC, Ingles J, Russell MW, Lakdawala NK, Ho CY, Day
10		S, Semsarian C, McDonough B, et al. Discordant clinical features of identical
11		hypertrophic cardiomyopathy twins. Proc Natl Acad Sci USA. 2021;118. doi:
12		10.1073/pnas.2021717118
13	4.	Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after
14		20 years: clinical perspectives. J Am Coll Cardiol. 2012;60:705-715. doi:
15		10.1016/j.jacc.2012.02.068
16	5.	Jansweijer JA, van Spaendonck-Zwarts KY, Tanck MWT, van Tintelen JP,
17		Christiaans I, van der Smagt J, Vermeer A, Bos JM, Moss AJ, Swan H, et al.
18		Heritability in genetic heart disease: the role of genetic background. Open Heart.
19		2019;6:e000929. doi: 10.1136/openhrt-2018-000929
20	6.	Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ,
21		Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to
22		sarcomeric gene mutations is characterized by impaired energy metabolism
23		irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776-1782. doi:
24		10.1016/s0735-1097(02)03009-7

1	7.	Christiaans I, Nannenberg EA, Dooijes D, Jongbloed RJ, Michels M, Postema PG,
2		Majoor-Krakauer D, van den Wijngaard A, Mannens MM, van Tintelen JP, et al.
3		Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth
4		Heart J. 2010;18:248-254. doi: 10.1007/bf03091771
5	8.	van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Winegrad S,
6		Schlossarek S, Carrier L, ten Cate FJ, Stienen GJ, van der Velden J. Cardiac myosin-
7		binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency,
8		deranged phosphorylation, and cardiomyocyte dysfunction. Circulation.
9		2009;119:1473-1483. doi: 10.1161/circulationaha.108.838672
10	9.	Nannenberg EA, Michels M, Christiaans I, Majoor-Krakauer D, Hoedemaekers YM,
11		van Tintelen JP, Lombardi MP, ten Cate FJ, Schinkel AF, Tijssen JG, et al. Mortality
12		risk of untreated myosin-binding protein C-related hypertrophic cardiomyopathy:
13		insight into the natural history. J Am Coll Cardiol. 2011;58:2406-2414. doi:
14		10.1016/j.jacc.2011.07.044
15	10.	Eckart RE, Scoville SL, Campbell CL, Shry EA, Stajduhar KC, Potter RN, Pearse LA,
16		Virmani R. Sudden death in young adults: a 25-year review of autopsies in military
17		recruits. Ann Intern Med. 2004;141:829-834. doi: 10.7326/0003-4819-141-11-
18		200412070-00005
19	11.	Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege
20		AA, Lafont A, Limongelli G, Mahrholdt H, et al. 2014 ESC Guidelines on diagnosis
21		and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis
22		and Management of Hypertrophic Cardiomyopathy of the European Society of
23		Cardiology (ESC). Eur Heart J. 2014;35:2733-2779. doi: 10.1093/eurheartj/ehu284
24	12.	Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS,
25		Nishimura RA, Ommen SR, Rakowski H, et al. 2011 ACCF/AHA Guideline for the

1		Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American
2		College of Cardiology Foundation/American Heart Association Task Force on
3		Practice Guidelines. Developed in collaboration with the American Association for
4		Thoracic Surgery, American Society of Echocardiography, American Society of
5		Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society
6		for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
7		J Am Coll Cardiol. 2011;58:e212-260. doi: 10.1016/j.jacc.2011.06.011
8	13.	Hindieh W, Adler A, Weissler-Snir A, Fourey D, Harris S, Rakowski H. Exercise in
9		patients with hypertrophic cardiomyopathy: A review of current evidence, national
10		guideline recommendations and a proposal for a new direction to fitness. J Sci Med
11		Sport. 2017;20:333-338. doi: 10.1016/j.jsams.2016.09.007
12	14.	Dejgaard LA, Haland TF, Lie OH, Ribe M, Bjune T, Leren IS, Berge KE, Edvardsen
13		T, Haugaa KH. Vigorous exercise in patients with hypertrophic cardiomyopathy. Int J
14		Cardiol. 2018;250:157-163. doi: 10.1016/j.ijcard.2017.07.015
15	15.	Aengevaeren VL, Gommans DHF, Dieker HJ, Timmermans J, Verheugt FWA,
16		Bakker J, Hopman MTE, MJ DEB, Brouwer MA, Thompson PD, et al. Association
17		between Lifelong Physical Activity and Disease Characteristics in HCM. Med Sci
18		Sports Exerc. 2019;51:1995-2002. doi: 10.1249/mss.0000000000002015
19	16.	Kwon S, Lee HJ, Han KD, Kim DH, Lee SP, Hwang IC, Yoon Y, Park JB, Lee H,
20		Kwak S, et al. Association of physical activity with all-cause and cardiovascular
21		mortality in 7666 adults with hypertrophic cardiomyopathy (HCM): more physical
22		activity is better. Br J Sports Med. 2021;55:1034-1040. doi: 10.1136/bjsports-2020-
23		101987
24	17.	Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports.
25		J Am Coll Cardiol. 2005;45:1364-1367. doi: 10.1016/j.jacc.2005.02.015

1	18.	Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064-1075. doi:
2		10.1056/NEJMra022783
3	19.	Jansen M, Christiaans I, van der Crabben SN, Michels M, Huurman R, Hoedemaekers
4		YM, Dooijes D, Jongbloed JDH, Boven LG, Lekanne Deprez RH, et al. BIO FOr
5		CARE: biomarkers of hypertrophic cardiomyopathy development and progression in
6		carriers of Dutch founder truncating MYBPC3 variants-design and status. Neth Heart
7		J. 2021;29:318-329. doi: 10.1007/s12471-021-01539-w
8	20.	Sammani A, Jansen M, Linschoten M, Bagheri A, de Jonge N, Kirkels H, van Laake
9		LW, Vink A, van Tintelen JP, Dooijes D, et al. UNRAVEL: big data analytics
10		research data platform to improve care of patients with cardiomyopathies using routine
11		electronic health records and standardised biobanking. Neth Heart J. 2019;27:426-
12		434. doi: 10.1007/s12471-019-1288-4
13	21.	Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, Duboc D,
14		Gimeno J, de Groote P, Imazio M, et al. Proposal for a revised definition of dilated
15		cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for
16		clinical practice: a position statement of the ESC working group on myocardial and
17		pericardial diseases. Eur Heart J. 2016;37:1850-1858. doi: 10.1093/eurheartj/ehv727
18	22.	Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA.
19		Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-
20		compaction: a step towards classification as a distinct cardiomyopathy. Heart.
21		2001;86:666-671. doi: 10.1136/heart.86.6.666
22	23.	Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH,
23		Watkins H, Neubauer S. Left ventricular non-compaction: insights from
24		cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46:101-105.
25		doi: 10.1016/j.jacc.2005.03.045

1	24.	James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ,
2		Judge DP, Calkins H. Exercise increases age-related penetrance and arrhythmic risk in
3		arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal
4		mutation carriers. J Am Coll Cardiol. 2013;62:1290-1297. doi:
5		10.1016/j.jacc.2013.06.033
6	25.	van Lint FHM, Hassanzada F, Verstraelen TE, Wang W, Bosman LP, van der Zwaag
7		PA, Oomen T, Calkins H, Murray B, Tichnell C, et al. Exercise does not influence
8		development of phenotype in PLN p.(Arg14del) cardiomyopathy. Neth Heart J.
9		2023;31:291-299. doi: 10.1007/s12471-023-01800-4
10	26.	Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Jr., Tudor-Locke
11		C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS. 2011 Compendium of Physical
12		Activities: a second update of codes and MET values. Med Sci Sports Exerc.
13		2011;43:1575-1581. doi: 10.1249/MSS.0b013e31821ece12
14	27.	Braverman AC, Harris KM, Kovacs RJ, Maron BJ. Eligibility and Disqualification
15		Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task
16		Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From
17		the American Heart Association and American College of Cardiology. Circulation.
18		2015;132:e303-309. doi: 10.1161/cir.000000000000243
19	28.	Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics.
20		Computational Statistics & Data Analysis. 2003;43:121-137. doi: 10.1016/s0167-
21		9473(02)00225-6
22	29.	Saberi S, Wheeler M, Bragg-Gresham J, Hornsby W, Agarwal PP, Attili A,
23		Concannon M, Dries AM, Shmargad Y, Salisbury H, et al. Effect of Moderate-
24		Intensity Exercise Training on Peak Oxygen Consumption in Patients With

1		Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. Jama. 2017;317:1349-
2		1357. doi: 10.1001/jama.2017.2503
3	30.	Klempfner R, Kamerman T, Schwammenthal E, Nahshon A, Hay I, Goldenberg I,
4		Dov F, Arad M. Efficacy of exercise training in symptomatic patients with
5		hypertrophic cardiomyopathy: results of a structured exercise training program in a
6		cardiac rehabilitation center. Eur J Prev Cardiol. 2015;22:13-19. doi:
7		10.1177/2047487313501277
8	31.	Andreassen K, Dejgaard LA, Lie Ø, Fink TS, Lunde IG, Edvardsen T, Haugaa KH,
9		Stokke MK. Exercise training during childhood and adolescence is associated with
10		favorable diastolic function in hypertrophic cardiomyopathy. Int J Cardiol.
11		2022;364:65-71. doi: 10.1016/j.ijcard.2022.06.042
12	32.	Luiten RC, Ormond K, Post L, Asif IM, Wheeler MT, Caleshu C. Exercise restrictions
13		trigger psychological difficulty in active and athletic adults with hypertrophic
14		cardiomyopathy. Open Heart. 2016;3:e000488. doi: 10.1136/openhrt-2016-000488
15	33.	Reineck E, Rolston B, Bragg-Gresham JL, Salberg L, Baty L, Kumar S, Wheeler MT,
16		Ashley E, Saberi S, Day SM. Physical activity and other health behaviors in adults
17		with hypertrophic cardiomyopathy. Am J Cardiol. 2013;111:1034-1039. doi:
18		10.1016/j.amjcard.2012.12.018
19	34.	Lampert R, Ackerman MJ, Marino BS, Burg M, Ainsworth B, Salberg L, Tome
20		Esteban MT, Ho CY, Abraham R, Balaji S, et al. Vigorous Exercise in Patients With
21		Hypertrophic Cardiomyopathy. JAMA Cardiol. 2023;8:595-605. doi:
22		10.1001/jamacardio.2023.1042
23	35.	Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, Camici PG. The
24		case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol.
25		2009;54:866-875. doi: 10.1016/j.jacc.2009.04.072

1	36.	Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ.
2		Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac
3		troponin T disease. Circulation. 2001;104:1380-1384. doi: 10.1161/hc3701.095952
4	37.	Podrid PJ, Fuchs T, Candinas R. Role of the sympathetic nervous system in the
5		genesis of ventricular arrhythmia. Circulation. 1990;82:I103-113.
6	38.	Cserne Szappanos H, Viola HM, Ito DW, Lim S, Mangala M, Holliday M, Barratt
7		Ross S, Semsarian C, Hill A, Dixon RE, Hool LC. Cytoskeletal disarray increases
8		arrhythmogenic vulnerability during sympathetic stimulation in a model of
9		hypertrophic cardiomyopathy. Sci Rep. 2023;13:11296. doi: 10.1038/s41598-023-
10		38296-2
11	39.	Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S,
12		Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a
13		disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232-2239.
14		doi: 10.1161/circulationaha.106.644682
15	40.	Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, Ward D, Kohli SK,
16		Page SP, Demetrescu C, et al. Prevalence of exercise-induced left ventricular outflow
17		tract obstruction in symptomatic patients with non-obstructive hypertrophic
18		cardiomyopathy. Heart. 2008;94:1288-1294. doi: 10.1136/hrt.2007.126003
19	41.	Kim JY, Choi EY, Kim W, Rim SJ. Left ventricular outflow obstruction occurs
20		immediately after exercise in patients with non-obstructive hypertrophic
21		cardiomyopathy. Rev Cardiovasc Med. 2021;22:469-473. doi: 10.31083/j.rcm2202053
22		

1 Tables

2 Table 1. Baseline characteristics stratified by quartiles of overall physical activity*

	Overall	Quartile 1	Quartile 2	Quartile 3	Quartile 4	
	(n=188)	(n=47)	(n =47)	(n =47)	(n=47)	p-value
Male sex	108 (57)	21 (45)	23 (49)	26 (55)	38 (81)	0.002
Age at presentation (years)	43.4±14.8	42.6±13.2	42.1±16.7	44.2±15.0	44.5±14.4	0.830
Proband	80 (43)	19 (40)	16 (34)	20 (43)	25 (53)	0.301
Maximum wall thickness (mm)	16±6	15±7	16±7	16±6	16±6	0.968
LV ejection fraction (%)	59±10	60±7	59±9	60±8	57±13	0.552
LV end-diastolic diameter (mm)	46±6	44±5	46±7	45±6	48±7	0.157
Left atrial diameter (mm)	40±7	39±6	40±7	40±10	40±6	0.962
Body surface area (m ²)	2.0 [1.8-2.1]	1.9 [1.8-2.1]	1.8 [1.8-2.1]	2.0 [1.7-2.1]	2.0 [1.9-2.1]	0.786

3 *Subject characteristics, stratified by average MET-hours/week of recreational and occupational physical activity quartiles before first clinical

4 presentation; (Quartile 1: 0-25 MET-hours/week); (Quartile 2: 26-56 MET-hours/week), (Quartile 3: 57-110 MET-hours/week); (Quartile 4: 113-

351 MET-hours/week). Values are shown as mean ± standard deviation, median (interquartile range) or counts (percentage). Abbreviations as in
 text.

Table 2. Associations of physical activity with primary endpoint (major 1

2 cardiomyopathy-related events)

	aHR*	95% CI	p-value
Overall physical activity (per 7.5 MET-hours/week of	1.00	1.00-1.00	0.900
AHA minimum recommended exercise level)			
High dynamic (per 1 MET-hours/week)	1.00	0.98-1.02	0.826
High static (per 1 MET-hours/week)	0.97	0.92-1.02	0.274

3 *Corrected for sex. Abbreviations as in text.

1 Table 3. Associations of physical activity with secondary endpoints (MVA, HF events,

2 SRT and cardiomyopathy penetrance)*

	aHR [†]	95% CI	P-value
MVA			
Overall physical activity (per 7.5 MET-hours/week of	1.00	1.00-1.00	0.422
AHA minimum recommended exercise level)			
High-dynamic (dichotomized by median 10 MET-	2.29	0.80-6.55	0.122
hours/week)			
High-dynamic (dichotomized by 75th percentile 23 MET-	2.70	1.01-7.24	0.049
hours/week)			
High static (per 1 MET-hours/week)	0.98	0.92-1.05	0.589
HF events	I		
Overall physical activity (per 7.5 MET-hours/week of	1.00	1.00-1.00	0.869
AHA minimum recommended exercise level)			
High-dynamic (per 1 MET-hours/week)	1.01	0.99-1.04	0.338
High-static (per 1 MET-hours/week)	0.95	0.83-1.08	0.432
SRT	1		
Overall physical activity (per 7.5 MET-hours/week of	1.00	1.00-1.00	0.810
AHA minimum recommended exercise level)			
High-dynamic (per 1 MET-hours/week)	0.97	0.93-1.01	0.169
High-static (per 1 MET-hours/week)	0.98	0.91-1.06	0.661
Cardiomyopathy penetrance			
Overall physical activity (per 7.5 MET-hours/week of	1.00	1.00-1.00	0.787
AHA minimum recommended exercise level)			
High-dynamic (per 1 MET-hours/week)	0.99	0.97-1.01	0.259
High-static (per 1 MET-hours/week)	1.00	0.97-1.02	0.774

3 *Associations were preferentially analyzed as continuous values and presented as such, or

4 presented using clinically meaningful cutoffs (e.g. recommended minimum of overall activity).

5 For high-dynamic exercise and the MVA outcome, however, the linearity assumption was

6 violated and data is presented in a dichotomized fashion. † Corrected for sex. Abbreviations as

7 in text.

1 Figure legends

2 Figure 1. Survival free from major cardiomyopathy-related events.

- 3 Kaplan-Meier curves showing cumulative survival free from MCE, stratified by quartiles of
- 4 MET-hours/week, for (A) overall physical activity; (B) High-dynamic exercise, (C) High-
- 5 static exercise. Abbreviations as in text.
- 6


7 Figure 2. Survival free from malignant ventricular arrhythmia.


- 8 Kaplan-Meier curves showing cumulative survival free from MVA, stratified by 75th
- 9 percentile MET-hours/week for high-dynamic exercise. Abbreviations as in text.

10

11 Figure 3. Cardiomyopathy penetrance

- 12 Kaplan-Meier curves showing cumulative survival free from cardiomyopathy penetrance,
- 13 stratified by the quartiles of MET-hours/week, for (A) overall physical activity (B) high
- 14 dynamic exercise and (C) high static exercise. Abbreviations as in text.





1 **Figure 2.**




Figure 3.

